Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Sulfasalazine neurotoxicity].

M L Chadenat1, S Morelon, C Dupont

  • 1Service de Médecine Interne 2 (Pr Rouveix), Hôpital Ambroise-Paré, 9, avenue Charles-de-Gaulle, 92104 Boulogne Cedex. marie-laurie.chadenat@apr.ap-hop-paris.fr

Annales De Medecine Interne
|July 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Embryotoxicity testing of IVF disposables: how do manufacturers test?

Human reproduction (Oxford, England)·2020
Same author

[How to promote hospital teams to users for their involvement in the actions of the perinatal networks?]

Gynecologie, obstetrique, fertilite & senologie·2019
Same author

Recurrence of a primary xanthoma of the humerus in a 9-year-old normolipidemic child.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2019
Same author

Nutritional risks of ARFID (avoidant restrictive food intake disorders) and related behavior.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2019
Same author

[Polycystic ovary syndrome does not affect blastulation nor cumulative live birth rates].

Gynecologie, obstetrique, fertilite & senologie·2019
Same author

[Overview of induction of labor practices in France].

Gynecologie, obstetrique, fertilite & senologie·2019

Sulfasalazine, a medication for polyarthritis, can rarely cause severe neurotoxicity, including seizures and acute encephalopathy. This case highlights a seldom-reported adverse effect of this common drug.

Area of Science:

  • Neurology
  • Rheumatology
  • Clinical Pharmacology

Background:

  • Sulfasalazine is a widely used disease-modifying antirheumatic drug (DMARD) for various inflammatory conditions, including polyarthritis.
  • While generally well-tolerated, sulfasalazine has been associated with a range of adverse effects, predominantly gastrointestinal and dermatological.
  • Neurological side effects are uncommon but have been documented.

Observation:

  • A female patient undergoing treatment for polyarthritis with sulfasalazine developed new-onset seizures and acute encephalopathy.
  • The patient's neurological symptoms emerged during the course of sulfasalazine therapy.
  • Other potential causes for the neurological presentation were considered and ruled out.

Findings:

  • The clinical presentation strongly suggested sulfasalazine-induced neurotoxicity.

Related Experiment Videos

  • This represents a rare but serious adverse reaction to sulfasalazine.
  • The case underscores the importance of considering drug-induced neurotoxicity in patients presenting with unexplained neurological symptoms.

    • Implications:

    • Clinicians should maintain a high index of suspicion for sulfasalazine neurotoxicity in patients with polyarthritis who develop neurological symptoms.
    • Early recognition and discontinuation of sulfasalazine may be crucial for favorable outcomes.
    • Further research into the mechanisms and risk factors for sulfasalazine neurotoxicity is warranted.